2.2.0.25truefalse40202 - Disclosure - ALLIANCES AND COLLABORATIONS (Summarized Financial Information Reflected in Consolidated Financial) (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse10/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_10_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-10-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2falsefalseUSDfalsefalse7/1/2010 - 9/30/2010
USD ($)
USD ($) / shares
$Duration_7_1_2010_To_9_30_2010http://www.sec.gov/CIK0000014272duration2010-07-01T00:00:002010-09-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse4/1/2010 - 6/30/2010
USD ($)
USD ($) / shares
$Duration_4_1_2010_To_6_30_2010http://www.sec.gov/CIK0000014272duration2010-04-01T00:00:002010-06-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4falsefalseUSDfalsefalse1/1/2010 - 3/31/2010
USD ($) / shares
USD ($)
$Duration_1_1_2010_To_3_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-03-31T00:00:00Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDfalsefalse10/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_10_1_2009_To_12_31_2009http://www.sec.gov/CIK0000014272duration2009-10-01T00:00:002009-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$6falsefalseUSDfalsefalse7/1/2009 - 9/30/2009
USD ($)
USD ($) / shares
$Duration_7_1_2009_To_9_30_2009http://www.sec.gov/CIK0000014272duration2009-07-01T00:00:002009-09-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$7falsefalseUSDfalsefalse4/1/2009 - 6/30/2009
USD ($)
USD ($) / shares
$Duration_4_1_2009_To_6_30_2009http://www.sec.gov/CIK0000014272duration2009-04-01T00:00:002009-06-30T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$8falsefalseUSDfalsefalse1/1/2009 - 3/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_3_31_2009http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-03-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$9falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Divide<
MeasureSchema>http://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$10falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$11falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$Duration_1_1_2008_To_12_31_20083http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false0us-gaap_SalesRevenueNetus-gaaptruecreditdurationNo definition available.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:monetaryItemTypemonetaryTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse3false0us-gaap_IncomeLossFromEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse313000000313falsefalsefalsefalsefalse10truefalsefalse550000000550falsefalsefalsefalsefalse11truefalsefalse617000000617falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any diffe
rence between cost and underlying equity in net assets of the investee at the date of investment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 19
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 11
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph b
falsefalse4false0us-gaap_OtherNonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalse
false00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse-126000000-126falsefalsefalsefalsefalse10truefalsefalse381000000381falsefalsefalsefalsefalse11truefalsefalse-22000000-22falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
falsefalse5false0bmy_DeferredIncomeCurrentAndNoncurrentbmyfalsecreditinstantThe aggregate amount of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse12970000001297falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefals
e5truefalsefalse11860000001186falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefal
se9truefalsefalse12970000001297falsefalsefalsefalsefalse10truefalsefalse11860000001186falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized, and is expected to be recognized in the next twelve months. Deferred income
is recorded when consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.No authoritative reference available.falsefalse6false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationreflectedinconsolidatedfinancialdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse12falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : License Fee [Member]
{invest_InvestmentAxis} : Irbesartan [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201022112http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseLicense Fee [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_LicenseFeeMemberdei_LegalEntityAxisexplicitMemberfalsefalseIrbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_IrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD<
/OriginalCurrencyCode>$13falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : License Fee [Member]
{invest_InvestmentAxis} : Irbesartan [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092291http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseLicense Fee [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_LicenseFeeMemberdei_LegalEntityAxisexplicitMemberfalsefalseIrbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_IrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : License Fee [Member]
{invest_InvestmentAxis} : Irbesartan [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20083220http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseLicense Fee [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_LicenseFeeMemberdei_LegalEntityAxisexplicitMemberfalsefalseIrbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_IrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse7false0us-gaap_OtherNonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse3100000031falsefalsefalsefalsefalse10truefalsefalse3200000032falsefalsefalsefalsefalse11truefalsefalse3100000031falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
falsefalse8false0bmy_DeferredIncomeCurrentAndNoncurrentbmyfalsecreditinstantThe aggregate amount of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse6000000060falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefal
se3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse9100000091falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse<
/hasScenarios>7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse6000000060falsefalsefalsefalsefalse10truefalsefalse9100000091falsefalsefalsefalsef
alse11falsefalsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate amount of deferred income as of balance sheet date. Deferred income is a liability related to a revenue or other income producing activity for which revenue or other income has not yet been recognized, and is expected to be recognized in the next twelve months. Deferred income is recorded when
consideration from a customer is received before achieving certain criteria that must be met for revenue or other income to be recognized in conformity with GAAP.No authoritative reference available.falsefalse9false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationreflectedinconsolidatedfinancialdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse15falsefalseUSDtruefalse{us-gaap_Bus
inessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Europe and Asia [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_20102230http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Europe and Asia [Member]dei_Lega
lEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringEuropeAndAsiaMemberdei_LegalEntityAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$16falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Europe and Asia [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_2009222http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Europe and Asia [Member]dei_Legal
EntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringEuropeAndAsiaMemberdei_LegalEntityAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Europe and Asia [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200843533http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Europe and Asia [Member]dei_Leg
alEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringEuropeAndAsiaMemberdei_LegalEntityAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse10false0us-gaap_IncomeLossFromEquityMethodInvestmentsus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefa
lsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse325000000325falsefalsefalsefalsefalse10truefalsefalse558000000558falsefalsefalsefalsefalse11truefalsefalse632000000632falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 19
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 11
-Article 7
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph b
falsefalse11false0us-gaap_EquityMethodInvestmentDividendsOrDistributionsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalse
false313000000313falsefalsefalsefalsefalse10truefalsefalse554000000554falsefalsefalsefalsefalse11truefalsefalse610000000610falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classifie
d as investing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 13
-Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 19
falsefalse12false0us-gaap_EquityMethodInvestmentsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse2200000022falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalse
false00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse1000000010falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse2200000022falsefalsefalsefalsefalse10truefalsefalse1000000010falsefalsefalsefalsefalse11falsefa
lsefalse00falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment losses recog
nized.No authoritative reference available.falsefalse13false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationrefl
ectedinconsolidatedfinancialdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalse<
hasSegments>falsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefa
lsefalse11falsefalsefalse00falsefalsefalsefalsefalse18falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010825http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest_
InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092284http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest
_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{invest_InvestmentAxis} : Clopidogrel Bisulfate And Irbesartan [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20083216http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseClopidogrel Bisulfate And Irbesartan [Member]invest
_InvestmentAxisxbrldihttp://xbrl.org/2006/xbrldibmy_ClopidogrelBisulfateAndIrbesartanMemberinvest_InvestmentAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definition available.No authoritative reference available.falsefalse14false0us-gaap_SalesRevenueNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefa
lsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse74640000007464falsefalsefalsefalsefalse10truefalsefalse69120000006912falsefalsefalsefalsefalse11truefalsefalse62960000006296falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse15false0us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefa
lsefalse20930000002093falsefalsefalsefalsefalse10truefalsefalse17170000001717falsefalsefalsefalsefalse11truefalsefalse14440000001444falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryDecrease in noncontrolling interest balance from payment of dividends or other distributions to noncontrolling interest holders.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(2)
falsefalse16false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationreflectedinconsolidatedfinancialdetails<
Cells>1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11<
IsNumeric>falsefalsefalse00falsefalsefalsefalsefalse21falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010322http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]de
i_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092221http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]d
ei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Territory Covering Americas and Australia [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20085http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseTerritory Covering Americas and Australia [Member]dei_
LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_TerritoryCoveringAmericasAndAustraliaMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo d
efinition available.No authoritative reference available.falsefalse17false0us-gaap_RoyaltyExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefals
efalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse13480000001348falsefalsefalsefalsefalse10truefalsefalse11990000001199falsefalsefalsef
alsefalse11truefalsefalse10610000001061falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.No authoritative reference available.falsefalse18false0bmy_NetIncomeLossAttributableToNoncontrollingInterestPretaxbmyfalsecreditdurationThe pre-tax portion of income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalse
false7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse
9truefalsefalse20740000002074falsefalsefalsefalsefalse10truefalsefalse17170000001717falsefalsefalsefalse<
hasScenarios>false11truefalsefalse14440000001444falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe pre-tax portion of income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.No authoritative reference available.falsefalse19false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationreflectedinconsolidatedfinancialdetails1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5false
falsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalse
false00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9falsefalsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse24falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Supply Activities and Development and Opt-out Royalties [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201022111http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseSupply Activities and Development and Opt-out Royalties [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SupplyActivitiesAndDevelopmentAndOptOutRoyaltiesMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25falsef
alseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Supply Activities and Development and Opt-out Royalties [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_20092290http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseSupply Activities and Development and Opt-out Royalties [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SupplyActivitiesAndDevelopmentAndOptOutRoyaltiesMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26falsefa
lseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Supply Activities and Development and Opt-out Royalties [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20083219http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseSupply Activities and Development and Opt-out Royalties [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SupplyActivitiesAndDevelopmentAndOptOutRoyaltiesMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$Other
naNo definition available.No authoritative reference available.falsefalse20false0us-gaap_OtherNonoperatingIncomeExpenseus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefa
lsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalse<
DisplayDateInUSFormat>falsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9truefalsefalse30000003falsefalsefalsefalsefalse10truefalsefalse4100000041falsefalsefalsefalsefalse11truefalsefalse7100000071falsefalsefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryThe net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.Reference 1: h
ttp://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 9
-Article 5
falsefalse21false0natruenanaNo definition available.falsetruefalsefalsefalsefalsefalsefalsefalsefalsehttp://www.bms.com/taxonomy/role/disclosurealliancesandcollaborationssummarizedfinancialinformationreflectedinconsolidatedfinancialdetails1<
/Id>falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3<
IsNumeric>falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsefalsefalse6falsefalsefalse00falsefalsefalsefalsefalse7
falsefalsefalse00falsefalsefalsefalsefalse8falsefalsefalse00falsefalsefalsefalsefalse9false
falsefalse00falsefalsefalsefalsefalse10falsefalsefalse00falsefalsefalsefalsefalse11falsefalsefalse00falsefalsefalsefalsefalse27falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Europe Comarketing Countries and Other [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201022126http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseEurope Comarketing Countries and Other [Member]dei
_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_EuropeComarketingCountriesAndOtherMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$28falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Europe Comarketing Countries and Other [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200922111http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseEurope Comarketing Countries and Other [Member]dei
_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_EuropeComarketingCountriesAndOtherMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Sanofi [Member]
{dei_LegalEntityAxis} : Europe Comarketing Countries and Other [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20083240http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseSanofi [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldibmy_SanofiMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseEurope Comarketing Countries and Other [Member]dei_
LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibmy_EuropeComarketingCountriesAndOtherMemberdei_LegalEntityAxisexplicitMemberUnit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$OthernaNo definit
ion available.No authoritative reference available.falsefalse22false0us-gaap_SalesRevenueNetus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseter
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:monetaryItemTypemonetaryTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse1121ALLIANCES AND COLLABORATIONS (Summarized Financial Information Reflected in Consolidated Financial) (Details) (USD $)MillionsUnKnownUnKnownUnKnownfalsetrue
